Submit to Biomedicines Review for Biomedicines Propose a Special Issue

Journal Menu

Journal Browser

Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (15 February 2022) | Viewed by 48074

Share This Special Issue

Special Issue Editors

Dr. Stefano Indraccolo

E-Mail Website
Guest Editor

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV—IRCCS, 35128 Padova, Italy
Interests: translational research; lung cancer and ovarian cancer; notch signaling in cancer; tumor angiogenesis and metabolism; mechanisms of resistance to antiangiogenic therapy; prognostic/predictive biomarker identification
Special Issues, Collections and Topics in MDPI journals

Dr. Paola Ulivi

E-Mail Website
Guest Editor

Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), via P. Maroncelli 40, 47014 Meldola, Italy
Interests: translational research; biomarkers; liquid biopsy; oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Liquid biopsy has emerged as new tool for detecting clinically relevant genetic alterations in cancer patients. The term liquid biopsy is commonly used not only to refer to molecular assays performed on cell-free DNA purified from plasma but can also include testing on other body fluids, such as urine and cerebrospinal fluid and measurements of circulating tumor cells, exosomes and circulating tumor RNA.

Here, we would like to focus on liquid biopsy approaches to track response to therapy in solid tumors. This special issue will cover studies investigating the significance of liquid biopsy for diagnostic/prognostic purposes as well as to predict patient outcome, compared with patient management guided via canonical molecular data and imaging modalities.

In this Special Issue, we welcome Original Research and Review articles focused on, but not limited to, dynamic measurements of mutations and other genetic alterations in plasma or other fluids. Studies on other liquid biopsy biomarkers such as microRNA and proteins are also considered.

You may choose our Joint Special Issue in International Journal of Molecular Sciences.

Dr. Stefano Indraccolo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (9 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Editorial

Jump to: Research, Review

2 pages, 167 KiB

Open AccessEditorial

Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis

by Paola Ulivi and Stefano Indraccolo

Biomedicines 2022, 10(11), 2748; https://doi.org/10.3390/biomedicines10112748 - 29 Oct 2022

Cited by 5 | Viewed by 1749

Abstract

Liquid biopsy has emerged as new tool for detecting clinically relevant genetic alterations in cancer patients [...] Full article

(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)

Research

Jump to: Editorial, Review

14 pages, 23182 KiB

Open AccessArticle

Cancer Detection Using an Artificial Secretable MicroRNA Found in Blood and Urine

by Pei-Wei Shueng, Kuang-Chung Shih, Sanjiv Sam Gambhir, Deng-Yu Kuo and Hui-Yen Chuang

Biomedicines 2022, 10(3), 621; https://doi.org/10.3390/biomedicines10030621 - 7 Mar 2022

Cited by 3 | Viewed by 2894

Abstract

Biomarkers can potentially help in the detection and prognosis of diseases such as cancer, its recurrence, predicting response to therapy, and monitoring of response during and/or after treatment. Endogenous tumor blood biomarkers suffer from low concentrations that are not distinguishable from background noise and, if identified, the localization of the biomarker production site is not known. The use of exogenously introduced or artificial biomarkers can eliminate these issues. In this study, we show that cancer cells can be made to produce an artificial secreted microRNA (Sec-miR) that can be detected in media from cells in culture, and from both blood and urine in living mice. In culture, we show that chaining a number of Sec-miR sequences in a plasmid and transfecting cells with the plasmids could increase Sec-miR secretion as the number of sequences increases. Tumor induction in mice with a stably transfected HeLa cell line shows the presence and significant increase in the Sec-miR with time and tumor growth in plasma (p < 0.001, R2 = 0.5542). The relative half-life of the Sec-miR was seen to be 1.2 h in the plasma of living mice and was seen to appear in urine within 12 h. The transgene for the Sec-miR within a minicircle was introduced via the tail-vein into subcutaneous tumor-bearing mice. As the tumor growth increased with time, further in vivo transfection of the Sec-miR minicircles showed an increase in Sec-miR in both plasma and urine (R2 = 0.4546). This study demonstrated that an exogenous Sec-miR biomarker would allow for early tumor detection using in vitro diagnostics techniques. Full article

(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)

► Show Figures

Figure 1

Figure 1
Sec-miR reporter expression from cells could be amplified by inserting multiple copies of Sec-miR into a single construct. Hela cells were transiently transfected with plasmids containing 1, 2, 4, 8, or 12 copies of Sec-miR driven by constitutive EF1 promoter or tumor-specific Survivin promoter (pSurv) in different wells. (A) All the Sec-miR expressions were normalized to the values in wells transfected with the 1X Sec-miR copy plasmid. Data are expressed as mean ± SD. Sec-miR expressions were detected in all the wells transfected with Sec-miR constructs; the Sec-miR expressions significantly increased as the copy numbers of Sec-miR increased in the plasmids. Moreover, Sec-miR expressions in the cells transfected with PP-pSurv-Sec-miR 12X-WPRE and MC-pSurv-Sec-miR 12X-WPRE were also compared. Sec-miR expressions of MC-transfected cells were significantly higher than PP-transfected cells and were comparable to the expressions detected in the cells transfected with pEF1-Luc2-Sec-miR 12X. (B) Bioluminescent signals emitted from cells transfected with different constructs were acquired after medium collection. *, p < 0.05; **, p < 0.01. Full article ">Figure 2
Sec-miR is detectable in the blood and urine of mice bearing Sec-miR-expressing Hela tumors and can be used as a complement to imaging reporters. Both parental Hela and the Hela cells stably express Luc2 and 8 copies of Sec-miR (Sec-miR 8X) were inoculated to mice; blood and urine of these tumor-bearing mice were collected and analyzed. Blood samples were collected once a week after the average tumor size reached 150 mm3. (A) Significantly higher Sec-miR expressions were detected in blood from mice with Hela/EF1-Luc2-Sec-miR 8X tumors, and the Sec-miR expression increased as the tumors grew. (B) Detectable Sec-miR expressions were found in urine from the mice with Hela/EF1-Luc2-Sec-miR 8X tumors from week 2 after tumor inoculation. The Sec-miR expressions did not increase as the tumor grew but varied over time. Correlations of tumor sizes and Sec-miR expressions in (C) blood and (D) urine. Data from Hela/EF1-Luc2-Sec-miR 8x mice are normalized to data from parental HeLa mice and expressed as mean ± SD. **, p < 0.01; ***, p < 0.001. Full article ">Figure 3
miRNA clearance in vivo. Normal mice were intravenously injected with 200 µL concentrated Sec-miR containing medium. The blood and urine samples were collected every 12 h for two days to determine the Sec-miR clearance in vivo. (A) Around 25% of Sec-miR expression was detected in the first blood sample (within 2 min after injection) compared to the injected Sec-miR-containing medium. Sec-miR expression in blood was significantly dropped in the first 12 h after injection and remained detectable until 36 h after injection. (B) Three of four Sec-miR injected mice showed around 10-fold expressions of Sec-miR in the first 12 h (0–12 h) urine samples. Decreased Sec-miR expressions were found in the second (12–24 h) and fourth (36–48 h) 12 h time period and came back in the third 12 h after injection. Full article ">Figure 4
Systemic delivery of tumor-specific Sec-miR MC allows the identification of tumor-bearing subjects. After the average tumor size reached 150 mm3, tumor-specific Sec-miR MCs (40 µg, N/P = 8) were injected systemically to tumor-bearing mice (Tumor + MC) and healthy normal mice (Normal + MC). Normal (tumor-free) mice received MCs (Normal + MC), and tumor-bearing mice that did not receive MCs (Tumor − MC) were served as control groups. Sec-miR expressions in blood were measured on day 2 after MC injection. Sec-miR expressions significantly increased in blood compared to Normal + MC and Tumor − MC groups. a, compared to Normal + MC, p < 0.01; b, compared to Tumor-MC, p < 0.05. Full article ">Figure A1
qPCR standard curve of Sec-miR. Different copy numbers of synthesized Sec-miR were spiked in 200 µL culture medium. The Sec-miR-containing medium was further processed with an RNA isolation kit and subjected to qPCR assay to generate a qPCR standard curve of Sec-miR. The X-axis is shown as the log 10 of the copy number per µL. Full article ">Figure A2
Representative BLI images of Hela/pEF1-Luc2-Sec-miR 8X mice. BLI images were acquired on weeks 2, 4, and 6 after tumor inoculation. Viable cells present in tumors seemed to decrease as the BLI signal reduced on Week 6 after tumor inoculation. Full article ">

8 pages, 761 KiB

Open AccessArticle

Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma

by Marlene Friedl, Stefan Stoiber, Faris F. Brkic and Lorenz Kadletz-Wanke

Biomedicines 2022, 10(1), 191; https://doi.org/10.3390/biomedicines10010191 - 17 Jan 2022

Cited by 4 | Viewed by 2324

Abstract

Background: A head and neck adenoid-cystic carcinoma is a rare malignant tumor arising from the salivary gland tissues. The long-term survival outcome is poor due to a high risk of recurrences and distant metastasis. The identification of prognostic markers could contribute to a better risk assessment of each patient. The aim of this study is to assess the potential prognostic value of serum albumin in patients with head and neck adenoid-cystic carcinomas. Patients and Methods: This retrospective cohort study included all patients treated for a head and neck adenoid-cystic carcinoma between 1993 and 1 June 2019 with available pretherapeutic albumin values and clinical follow-up data. The cohort was stratified into a high and low group according to the median albumin value. The log-rank test was used for comparing overall and disease-free survival. Results: A total of 37 patients with complete follow-up data and available pretreatment albumin values were available. The overall mortality and recurrence rates were 21.6% (n = 8) and 45.9% (n = 17), respectively. Survival was shorter in the low albumin group. In particular, the mean overall survival for the low and high albumin groups were 121.0 months and 142.8 months, respectively. However, the difference was not statistically significant (p = 0.155). A statistically significant difference was observed in context with disease-free survival (45.2 months, 95% confidence interval 31.7–58.8 months vs. 114.8 months, 95% confidence interval 79.3–150.4 months; p = 0.029). Conclusion: Our study suggests a potential prognostic value of serum albumin in patients with a head and neck ACC. A further, external validation of our results is warranted. Full article

(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)

► Show Figures

Figure 1

12 pages, 1723 KiB

Open AccessArticle

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience

by Paola Ulivi, Elisabetta Petracci, Matteo Canale, Ilaria Priano, Laura Capelli, Daniele Calistri, Elisa Chiadini, Paola Cravero, Alice Rossi, Angelo Delmonte, Lucio Crinò and Giuseppe Bronte

Biomedicines 2021, 9(10), 1299; https://doi.org/10.3390/biomedicines9101299 - 23 Sep 2021

Cited by 11 | Viewed by 2692

Abstract

Background: Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from NSCLC patients has become routine. The aim of this study was to explore its applicability in clinical practice. Methods: We collected data of EGFR-mutated NSCLC patients with liquid biopsy analysis. Data included test timing, concomitant tissue re-biopsy, therapy change, histology, stage, smoking habits, gender and age. All analyses were performed via a real-time PCR method to analyze EGFR mutations at exons 18, 19, 20 and 21. Variant allele frequency was performed for patients with available sequential EGFR mutation analysis in cfDNA. Overall survival was analyzed through the Kaplan–Meier method. We designed flow charts to show the real-life application of liquid biopsy. Results: We found that liquid biopsy is used in treatment-naïve patients as an alternative to EGFR detection in tumor tissue, and in patients with positive or negative EGFR from tumor biopsy. The majority of liquid biopsy analyses were performed in NSCLC patients who were disease progressive during TKI therapy. The presence of EGFR mutation in cfDNA was associated with a worse prognosis. In two patients, VAF of EGFR mutations in cfDNA was concordant with tumor volume changes. Conclusion: These findings suggest that liquid biopsy for EGFR detection can continue to be useful. Full article

(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)

► Show Figures

Figure 1

Figure 1
Samples from treatment-naïve patients and flow-chart of routine EGFR mutation analysis. Full article ">Figure 2
Flow-chart for EGFR mutation analysis for patients in progressive disease after TKI treatment. Full article ">Figure 3
Overall survival (OS) of patients by EGFR mutation in cfDNA. Full article ">Figure 4
History of disease of the patient described as Case 1. Radiologic responses to TKI treatment paired with circulating activating and resistance EGFR mutation. CT shows reduction in size both of lung cancer (*) and pleural effusion (^) localized in the right lung from baseline (A) to the fist control (B). Relapse with complete filling of right pulmonary air spaces, malignant pleural thickness (blu arrow) and pleural effusion (C,D). Longitudinal VAF of L858R and T790M mutations in cfDNA (E). Full article ">Figure 5
History of disease of the patient described as Case 2. Radiologic responses to TKI treatment paired with circulating activating and resistance EGFR mutation. PET-CT Images show size reduction without FDG-uptake, consisting with complete response, of the lung cancer localized in the left upper lobe (*) and adenopathy at subcarinal level (˄) from baseline (A) to controls at 3 and 6 months (B,C); PET-CT in the fourth image shows a relapse of tumor (D). Longitudinal VAF of delEx19 and T790M mutations in cfDNA (E). Full article ">

12 pages, 2338 KiB

Open AccessEditor’s ChoiceArticle

ExoCAS-2: Rapid and Pure Isolation of Exosomes by Anionic Exchange Using Magnetic Beads

by Hyunsung Kim and Sehyun Shin

Biomedicines 2021, 9(1), 28; https://doi.org/10.3390/biomedicines9010028 - 2 Jan 2021

Cited by 34 | Viewed by 11312

Abstract

Extracellular vesicles (EVs) are considered essential biomarkers in liquid biopsies. Despite intensive efforts aimed at employing EVs in a clinical setting, workable approaches are currently limited owing to the fact that EV-isolation technologies are still in a nascent stage. This study introduces a magnetic bead-based ion exchange platform for isolating EVs called ExoCAS-2 (exosome clustering and scattering). Owing to their negative charge, exosomes can easily adhere to magnetic beads coated with a polycationic polymer. Owing to the features of magnetic beads, exosomes can be easily processed via washing and elution steps and isolated with high purity and yield within 40 min. The present results confirmed the isolation of exosomes through analyses of size distribution, morphology, surface and internal protein markers, and exosomal RNA. Compared with the commercially available methods, the proposed method showed superior performance in terms of key aspects, including operation time, purity, and recovery rate. This highlights the potential of this magnetic bead-based ion exchange platform for isolating exosomes present in blood plasma. Full article

(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)

► Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
Schematic for extracellular vesicles (EV) isolation using cationic polymer-coated beads. Experimental procedure in which magnetic beads coated with cationic poly-L-lysine (PLL) polymer were mixed with anionic exosomes. Exosome-bound beads were washed and isolated via a magnetic feature. Full article ">Figure 2
EV isolation using cationic polymer-coated beads. (A) SEM images of a PLL-coated bead, an EV-captured PLL bead, and isolated exosomes, respectively. The mean size of the magnetic beads was 950 nm. (B) Fluorescent images of PLL-coated magnetic beads (green color), exosome capture by PLL bead (red color), and the merged image. (C) Cryo-TEM images of EVs eluted from PLL beads and ultracentrifugation (UC). (D) Zeta potentials of exosomes, PLL beads, EV-bound PLL beads, and plasma proteins, including albumin, γ-globulin, and fibrinogen. (E) Volume-change analysis after incubating PLL beads with blood plasma. Full article ">Figure 3
Comparison of EV isolation methods (EQ, UC, exoEasy, PLL-beads) using NTA, and BCA. (A) Mean size. (B,C) Particle concentration and protein concentration (*: p < 0.05, **: p < 0.01, ***: p < 0.001). (D) Normalized purity ratio (particle/protein ratio), using UC as a reference standard for both particle and purity ratio (dotted line). EQ: ExoQuick (SBI), UC: ultracentrifugation, exoEasy (Qiagen), ExoCAS-2: present research. Full article ">Figure 4
Comparison of EV isolation methods (EQ, UC, exoEasy, PLL beads) using bioanalyzer, western blot, RT-qPCR, and microarray. (A) Western blot for investigating protein markers of EVs. (B) Western blot analysis for proteins extracted from EVs. (C) Analysis of total exosomal RNA using bioanalyzer with Agilent eukaryote total RNA pico chips. (D) Exosomal miRNAs (hsa-let-7a-5p, hsa-miR-142-3p) measured by RT-qPCR. (E,F) Venn diagram and heatmap depicting gene expression by microarray analysis. EQ: ExoQuick (SBI), UC: ultracentrifugation, exoEasy (Qiagen), ExoCAS-2: present research. Full article ">Figure 5
Optimization of washing and eluting processes under the current PLL-coated magnetic bead-based ion exchange method. (A) Washing step to remove undesired proteins. (B,C) Particle concentration, protein concentration, and washing efficiency (protein/particle ratio) in the washing step (*: p < 0.05, **: p < 0.01). (D) Elution step to collect pure exosomes. (E,F) Particle concentration, protein concentration, and elution efficiency (particle/protein ratio) in the elution step. (Grey arrow: the coordinates of the bar in the figure; Red arrow: the coordinates of the line in the figure). Full article ">

12 pages, 834 KiB

Open AccessArticle

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

by Zlata Huskova, Jana Knillova, Zdenek Kolar, Jana Vrbkova, Milan Kral and Jan Bouchal

Biomedicines 2020, 8(6), 173; https://doi.org/10.3390/biomedicines8060173 - 25 Jun 2020

Cited by 7 | Viewed by 3497

Abstract

The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5–10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy. Full article

(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)

► Show Figures

Figure 1

Figure 1
Urine markers are differentially expressed between CaP and BPH. (A) Description of the whole cohort and a subset of patients analyzed for indicated transcripts. (B) AMACR, PCA3, TRPM8 and EZH2 expression were significantly different for CaP and BPH patients (p values 0.045, 0.004, 0.005 and 0.019, respectively). (C) Percentage of free PSA in combination with urine markers contribute to discrimination of BPH from CaP. Percentage of free PSA significantly discriminates CaP from BPH (p value 0.003). Box-plots represent median, 25–75% percentiles and range of values. p-values <0.05 and <0.01 are indicated by * and **, respectively. (D) Receiver-operating characteristic analysis for % free PSA in combination with urinary markers AMACR and PCA3 or (E) with EPCAM, PCA3 and PSGR in the subset of patients. Full article ">Figure 2
Inflammation in BPH tissue affects serum PSA and urine PCA3. Serum PSA levels (A) and to a lesser extent also urine PCA3 (B) were significantly higher in patients with inflamed BPH tissue (p values 0.005 and 0.040, respectively). Box-plots represent median, 25–75% percentiles and range of values. p-values <0.05 and <0.01 are indicated by * and **, respectively. Full article ">

14 pages, 2356 KiB

Open AccessArticle

When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients

by Chiara Foroni, Natasa Zarovni, Laura Bianciardi, Simona Bernardi, Luca Triggiani, Davide Zocco, Marta Venturella, Antonio Chiesi, Francesca Valcamonico and Alfredo Berruti

Biomedicines 2020, 8(5), 131; https://doi.org/10.3390/biomedicines8050131 - 22 May 2020

Cited by 39 | Viewed by 4537

Abstract

We evaluated the advantages and the reliability of novel protocols for the enrichment of tumor extracellular vesicles (EVs), enabling a blood-based test for the noninvasive parallel profiling of multiple androgen receptor (AR) gene alterations. Three clinically relevant AR variants related to response/resistance to standard-of-care treatments (AR-V7 transcript, AR T878A point mutation and AR gene amplification) were evaluated by digital PCR in 15 samples from patients affected by Castration-Resistant Prostate Cancer (CRPC). Plasma was processed to obtain circulating RNA and DNA using protocols based on tumor EVs enrichment through immuno-affinity and peptide-affinity compared to generic extraction kits. Our results showed that immuno-affinity enrichment prior to RNA extraction clearly outperforms the generic isolation method in the detection of AR-V7, also allowing for a distinction between responder (R) and non-responder (NR) patients. The T878A mutation was detected, overall, in nine out of 15 samples and no approach alone was able to reveal mutations in all harboring samples, showing that the employed methods complement each other. AR amplification was detected in the majority of CRPC samples analysed using either cell-free DNA (cfDNA) or exosome isolation kits (80%). We demonstrated that selective isolation of a subset of circulating exosomes enriched for tumor origin, rather than analysis of total plasma exosomes, or total plasma nucleic acids, increases sensitivity and specificity for the detection of specific alterations. Full article

(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)

► Show Figures

Figure 1

Figure 1
(A) Androgen receptor (AR)-V7 and (B) RNY4 copies/mL (respectively) detected with immune-affinity (IA)-RNA protocol and generic RNA protocol. (C) Normalized AR-V7 copies/mL. Note that the IA-RNA protocol isolated overall much less RNA than the exoRNeasy method. (D) AR-V7 and RNY4 copies/mL detected on whole plasma in a subset of samples. Full article ">Figure 2
(A) AR-V7 and (B) normalized AR-V7 copies/mL, in responder (R) and non-responder (NR) samples detected with the IA-RNA protocol, the generic RNA protocol and the PA-RNA protocol. The IA-RNA protocol distinguished between R and NR patients better than the other protocols on the basis of normalized AR-V7 results. (C) The average AR-V7 allelic frequency detected after IA-based enrichment and generic extraction, evaluated as: AR-V7 copies/WT copies + AR-V7 copies). (D) The difference between the NR and the R patients for the two isolation methods. Full article ">Figure 3
(A) AR-FL copies/mL identified with IA-RNA protocol vs. generic protocol, (B) with IA-RNA protocol vs. PA-RNA protocol and (C) in whole plasma in a subset of samples. Full article ">Figure 4
(A) AR T878A copies/mL identified with the column-based DNA purification (PA-DNA) protocol, the generic DNA protocol Kit and the IA-A protocol. (B) Results of the isolation for detection (with mutation copies/mL plasma)/non detection (✘) of the point mutation. Full article ">Figure 5
AR gene amplification evaluated based on the ratio between AR and RNaseP copies as internal controls (as previously described in [<a href="#B16-biomedicines-08-00131" class="html-bibr">16</a>]). The threshold for positiveness was set at 1.5. Full article ">Figure 6
Prediction for a sample to be R or NR based on each single parameter and arbitrary thresholds. In green, the correct correlation with the predicted status according to clinical, instrumental and biochemical parameters. Full article ">

Review

Jump to: Editorial, Research

20 pages, 1230 KiB

Open AccessReview

Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR

by Irina Palacín-Aliana, Noemí García-Romero, Adrià Asensi-Puig, Josefa Carrión-Navarro, Víctor González-Rumayor and Ángel Ayuso-Sacido

Biomedicines 2021, 9(8), 906; https://doi.org/10.3390/biomedicines9080906 - 28 Jul 2021

Cited by 39 | Viewed by 11467

Abstract

Cancer is one of the leading causes of death worldwide and remains a major public health challenge. The introduction of more sensitive and powerful technologies has permitted the appearance of new tumor-specific molecular aberrations with a significant cancer management improvement. Therefore, molecular pathology profiling has become fundamental not only to guide tumor diagnosis and prognosis but also to assist with therapeutic decisions in daily practice. Although tumor biopsies continue to be mandatory in cancer diagnosis and classification, several studies have demonstrated that liquid biopsies could be used as a potential tool for the detection of cancer-specific biomarkers. One of the main advantages is that circulating free DNA (cfDNA) provides information about intra-tumoral heterogeneity, reflecting dynamic changes in tumor burden. This minimally invasive tool has become an accurate and reliable instrument for monitoring cancer genetics. However, implementing liquid biopsies across the clinical practice is still ongoing. The main challenge is to detect genomic alterations at low allele fractions. Droplet digital PCR (ddPCR) is a powerful approach that can overcome this issue due to its high sensitivity and specificity. Here we explore the real-world clinical utility of the liquid biopsy ddPCR assays in the most diagnosed cancer subtypes. Full article

(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)

► Show Figures

Figure 1

22 pages, 1774 KiB

Open AccessReview

Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer

by Patricia Mondelo-Macía, Jorge García-González, Luis León-Mateos, Adrián Castillo-García, Rafael López-López, Laura Muinelo-Romay and Roberto Díaz-Peña

Biomedicines 2021, 9(1), 48; https://doi.org/10.3390/biomedicines9010048 - 7 Jan 2021

Cited by 24 | Viewed by 5950

Abstract

Approximately 19% of all cancer-related deaths are due to lung cancer, which is the leading cause of mortality worldwide. Small cell lung cancer (SCLC) affects approximately 15% of patients diagnosed with lung cancer. SCLC is characterized by aggressiveness; the majority of SCLC patients present with metastatic disease, and less than 5% of patients are alive at 5 years. The gold standard of SCLC treatment is platinum and etoposide-based chemotherapy; however, its effects are short. In recent years, treatment for SCLC has changed; new drugs have been approved, and new biomarkers are needed for treatment selection. Liquid biopsy is a non-invasive, rapid, repeated and alternative tool to the traditional tumor biopsy that could allow the most personalized medicine into the management of SCLC patients. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) are the most commonly used liquid biopsy biomarkers. Some studies have reported the prognostic factors of CTCs and cfDNA in SCLC patients, independent of the stage. In this review, we summarize the recent SCLC studies of CTCs, cfDNA and other liquid biopsy biomarkers, and we discuss the future utility of liquid biopsy in the clinical management of SCLC. Full article

(This article belongs to the Special Issue Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis)

► Show Figures

Journal Menu

Journal Browser

Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis

Share This Special Issue

Special Issue Editors

Special Issue Information

Benefits of Publishing in a Special Issue

Published Papers (9 papers)

Editorial

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI